Article
Targeting glucocorticoid-induced CD20 activation in preclinical models of B-ALL
2025-12-18
Abstract excerpt
Pediatric B-cell acute lymphoblastic leukemia (B-ALL) is effectively controlled with contemporary multi-agent chemotherapy, resulting to 5-year survival rates above 90%. However, relapse occurs in 15-20% of patients due to minimal residual disease (MRD), characterized by the presence of persisting and resistant leukemic cells, and associated with a poor clinical outcome. Despite its prognostic relevance, the molec...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 6c4204de-c163-5443-9711-1e68caaa37a0
- DOI
- 10.64898/2025.12.16.694550
